Invivyd Inc Dossier
Qualitative Analysis
Business overview
Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing antibody-based solutions for serious viral infectious diseases, with a primary focus on SARS-CoV-2. The company utilizes a proprietary integrated technology platform designed to rapidly assess, monitor, develop, and adapt to create best-in-class monoclonal antibodies (mAbs). Its lead commercialized product, PEMGARDA (pemivibart), has received Emergency Use Authorization (EUA) from the U.S. FDA for the pre-exposure prophylaxis of COVID-19 in certain immunocompromised individuals.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A comprehensive clinical program designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19, primarily focusing on the development of VYD2311 through the DECLARATION and LIBERTY Phase 3 trials.
Expected impact: Establish VYD2311 as a leading vaccine-alternative monoclonal antibody for vulnerable and immunocompromised populations.
Development of VBY329, a novel, potentially best-in-class monoclonal antibody candidate generated by Invivyd's proprietary discovery platform to prevent RSV in neonates, infants, and children.
Expected impact: Position the company to capture a share of the global pediatric RSV prophylaxis market, projected to reach $3-$4 billion by 2030.
Advancement of VMS063, a novel, highly potent, broadly neutralizing monoclonal antibody candidate engineered to target a highly conserved protein of the measles virus.
Expected impact: Establish a potentially first- and best-in-class therapeutic and preventative option for measles.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Launches the 'Antibodies for Any Body' national multimedia education campaign to elevate public understanding of antibodies and their role in disease prevention, enhancing brand visibility and market adoption.
Terms: Not publicly disclosed.
Collaboration to initiate a Phase 2 clinical trial evaluating VYD2311 in individuals suffering from Long COVID or COVID vaccine injury.
Terms: Not publicly disclosed.
Collaboration agreement for the discovery and optimization of proprietary antibodies using Adimab's platform.
Terms: Not publicly disclosed.